TD Asset Management Inc Buys 58,252 Shares of Sanofi $SNY

TD Asset Management Inc lifted its stake in Sanofi (NASDAQ:SNY) by 20.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 337,539 shares of the company’s stock after purchasing an additional 58,252 shares during the period. TD Asset Management Inc’s holdings in Sanofi were worth $15,932,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of SNY. Caprock Group LLC acquired a new stake in Sanofi in the third quarter worth about $1,347,000. Assetmark Inc. lifted its position in Sanofi by 25.0% during the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock valued at $16,859,000 after purchasing an additional 71,356 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Sanofi by 10,152.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock valued at $103,846,000 after purchasing an additional 2,178,647 shares during the last quarter. NewEdge Wealth LLC grew its position in shares of Sanofi by 63.1% during the 3rd quarter. NewEdge Wealth LLC now owns 67,303 shares of the company’s stock worth $3,298,000 after buying an additional 26,035 shares during the period. Finally, Willis Investment Counsel grew its position in shares of Sanofi by 11.3% during the 3rd quarter. Willis Investment Counsel now owns 556,700 shares of the company’s stock worth $26,276,000 after buying an additional 56,500 shares during the period. Institutional investors own 14.03% of the company’s stock.

Sanofi Trading Up 0.6%

NASDAQ SNY opened at $48.66 on Monday. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. The firm has a market cap of $118.68 billion, a P/E ratio of 13.52, a P/E/G ratio of 1.26 and a beta of 0.45. The stock’s 50-day moving average is $47.54 and its 200-day moving average is $48.58.

Analysts Set New Price Targets

SNY has been the topic of a number of recent research reports. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Guggenheim lowered Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Finally, Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Sanofi currently has a consensus rating of “Hold” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.